Abstract
The present studies have demonstrated that the growth hormone releaseinhibiting factor of the hypothalamus, somatostatin, exerts a prominent inhibiting action on glucose induced insulin release in man. This inhibition of insulin release could not be reversed by infusion of the alpha-adrenergic blocking agent, phentolamine. Our findings therefore suggest that the inhibiting effect of somatostatin on glucose induced insulin release is not mediated by the alpha-adrenergic receptors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
